Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$22.00 +3.5%	$19.28	$15.47 ▼ $36.37	$752.69M	1.47	189,312 shs	588,331 shs
PRQR ProQR Therapeutics	$1.79 +7.5%	$1.47	$1.07 ▼ $4.62	$187.81M	0.35	635,127 shs	300,849 shs
RCKT Rocket Pharmaceuticals	$2.77 +10.4%	$6.20	$2.19 ▼ $26.98	$295.80M	1.02	1.91 million shs	8.61 million shs
REPL Replimune Group	$9.57 +6.6%	$8.39	$4.93 ▼ $17.00	$737.72M	0.68	951,003 shs	2.32 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+3.92%	-0.47%	-3.77%	+9.22%
PRQR ProQR Therapeutics	0.00%	+0.60%	-15.58%	-21.13%	-13.85%
RCKT Rocket Pharmaceuticals	0.00%	-60.45%	-69.04%	-71.79%	-88.37%
REPL Replimune Group	0.00%	+6.95%	-10.79%	-26.32%	+69.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.2002 of 5 stars	3.6	0.0	0.0	3.0	0.0	0.0
PRQR ProQR Therapeutics	2.9299 of 5 stars	4.6	3.0	0.0	3.5	0.0	0.0
RCKT Rocket Pharmaceuticals	4.7995 of 5 stars	4.2	2.0	4.7	2.2	5.0	1.3
REPL Replimune Group	4.2242 of 5 stars	3.6	1.0	4.5	4.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	78.57% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	348.18% Upside
RCKT Rocket Pharmaceuticals	2.44	Hold	$21.21	665.86% Upside
REPL Replimune Group	3.11	Buy	$19.75	106.37% Upside

Current Analyst Ratings Breakdown

Latest PRQR, AVBP, RCKT, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
PRQR ProQR Therapeutics	$18.97M	9.90	N/A	N/A	$0.55 per share	3.25
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.43M	-$0.35	N/A	N/A	N/A	-134.31%	-71.58%	-19.70%	8/7/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	8/6/2025 (Estimated)

Latest PRQR, AVBP, RCKT, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
PRQR ProQR Therapeutics	N/A	2.33	2.33
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
PRQR ProQR Therapeutics	32.65%
RCKT Rocket Pharmaceuticals	98.39%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
PRQR ProQR Therapeutics	8.40%
RCKT Rocket Pharmaceuticals	24.76%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
PRQR ProQR Therapeutics	180	105.21 million	74.82 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
REPL Replimune Group	210	77.09 million	70.24 million	Optionable

PRQR, AVBP, RCKT, and REPL Headlines

Recent News About These Companies

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2 at 10:43 AM | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1 at 10:00 AM | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1 at 3:59 AM | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1 at 3:09 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31 at 12:48 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30 at 12:41 PM | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30 at 3:38 AM | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

HC Wainwright Estimates Replimune Group Q3 Earnings

May 27, 2025 | marketbeat.com

Analysts Offer Predictions for Replimune Group Q1 Earnings

May 27, 2025 | americanbankingnews.com

Leerink Partnrs Estimates Replimune Group Q1 Earnings

May 27, 2025 | marketbeat.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

May 25, 2025 | marketbeat.com

Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 25, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's Why

May 24, 2025 | marketbeat.com

Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)

May 24, 2025 | marketbeat.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings

May 24, 2025 | nasdaq.com

Replimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)

May 24, 2025 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript

May 23, 2025 | insidermonkey.com

Emily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

May 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, AVBP, RCKT, and REPL Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$22.00 +0.75 (+3.53%)

Closing price 04:00 PM Eastern

Extended Trading

$22.01 +0.01 (+0.05%)

As of 04:04 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ProQR Therapeutics NASDAQ:PRQR

$1.78 +0.13 (+7.53%)

Closing price 03:59 PM Eastern

Extended Trading

$1.79 +0.01 (+0.28%)

As of 04:18 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.77 +0.26 (+10.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.78 +0.02 (+0.54%)

As of 04:17 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Replimune Group NASDAQ:REPL

$9.57 +0.59 (+6.57%)

Closing price 04:00 PM Eastern

Extended Trading

$9.74 +0.17 (+1.79%)

As of 04:18 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time